The PROtective VEntilation Network (PROVE Network), is a collaborative initiative supported by the European Society of Anaesthesiology and Intensive Care (ESAIC). Its mission is to conduct impactful multicenter clinical studies in mechanical ventilation, exploring novel strategies to enhance patient care and safety in operating rooms (OR) and intensive care units (ICU) through rigorous research in mechanical ventilation. Established in 2014, the PROVE Network operates without a time limit, extending yearly based on project relevance and comprehensive reports submitted to the Research Committee. ESAIC not only endorses but actively facilitates communication among PROVE Network Research Groups, reinforcing the commitment to advancing patient care through collaborative research.
In this month’s newsletter, we interviewed Prof Marcus J. Schultz, highlighting his recent appointment as chair and spokesperson for the PROtective VEntilation Network (PROVE Network). Discover the mission of the PROVE Network, which focuses on testing innovative ventilation strategies and devices to enhance the care and safety of patients in need of mechanical ventilation.
I. Following the unfortunate passing of Prof Paolo Pelosi, when did you take over the role, and what responsibilities does it now entail?
After the passing of Prof Paolo Pelosi, I assumed the role of chair and spokesperson for the PROtective VEntilation Network (PROVE Network) taking over his responsibilities. Previously, the network was led by Paolo Pelosi, Marcelo Gamma de Abreu, Sabrine Hemmes, and Ary Serpa Neto, with Paolo serving as the chair and spokesperson.
Simultaneously, as part of a pre-existing plan, we established three distinct sections within the network: one dedicated to Randomized Controlled Trials (RCTs), another for observational studies, and a third for secondary analyses and meta-analyses. These sections are led by Chiara Robba and Denise Battaglini (RCTs), Sabrine Hemmes and Lorenzo Ball (observational studies), Ary Serpa Neto, with the support of Guido Mazzinari and David van Meenen (secondary analyses and meta-analyses).
In my role, I am assisted by Marcelo Gamma de Abreu.
II. Could you please provide a brief overview of the PROVE Network project, its primary objectives and the ongoing projects and studies?
The PROtective VEntilation Network (PROVE Network) aims to conduct or support adequately sized trials and studies, either nationally or internationally, with the aim of enhancing healthcare in operating rooms (OR) and intensive care units (ICU). Additionally, the PROVE Network functions as a platform for young investigators, including those who may be senior investigators early in their careers, PhD students, students, and anyone interested in learning about research. Furthermore, the PROVE Network collaborates with preclinical investigators in various laboratories worldwide.
Large studies until now, include but are not restricted toPReVENT, NEBULAE, RELAx, PRoVENT, LAMINaR, HepBurn, PRoVENT-iMiC, PROVHILO, LAS VEGAS, AVATaR, PROBESE, and the ongoing PROTHOR, DESIGNATION, and GENERATOR; soon the successors of PRoVENT, named PRoVENT2+, and of LAS VEGAS, named MEET VENUS will start.
III. What are the next steps in the development and implementation of the PROVE Network initiative?
The PROtective VEntilation Network (PROVE Network) continues to serve as a platform for studies on ventilation in operating rooms (OR) and intensive care units (ICU). It welcomes collaboration from researchers keen on contributing, learning, and enhancing outcomes for ventilated patients. Currently, efforts are underway to actively secure funding, creating opportunities for additional studies.